Ruxolitinib treatment is efficacious in patients with int-2 or high-risk myelofibrosis regardless of anemia or transfusion status, according to a study involving 528 individuals. Data were pooled from the COMFORT I and II trials, in which patients could cross over to ruxolitinib from either placebo or best available therapy, which all continuing patients did. Investigators looked at overall survival in treatment (n=301) and control (n=227) groups, as well as by baseline anemia and transfusion status at week 24. Among the results:
- Mortality risk was reduced by 30% in patients randomized to ruxolitinib, compared with patients in the control group (median of 5.3 and 3.8 years, respectively).
- Overall survival was longer for patients originally randomized to ruxolitinib vs those who crossed over (5.3 and 2.3 years, respectively).
- Ruxolitinib prolonged overall survival vs control (5.3 and 2.4 years, respectively).
- Survival benefit was seen with ruxolitinib regardless of baseline anemia.
Verstovsek S, Gotlib J, Mesa R, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10(1):156. doi:10.1186/s13045-017-0527-7.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al